UK markets open in 6 hours 35 minutes

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
20.13-0.38 (-1.85%)
At close: 04:00PM EDT
20.20 +0.07 (+0.35%)
After hours: 07:11PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.92B
Enterprise value 2.04B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.76
Price/book (mrq)2.01
Enterprise value/revenue 6.90
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.39
52-week change 3-34.91%
S&P500 52-week change 326.49%
52-week high 333.31
52-week low 314.56
50-day moving average 318.68
200-day moving average 319.91

Share statistics

Avg vol (3-month) 31.21M
Avg vol (10-day) 31.1M
Shares outstanding 5142.61M
Implied shares outstanding 6145.3M
Float 8123.16M
% held by insiders 113.68%
% held by institutions 184.46%
Shares short (30 Apr 2024) 410.5M
Short ratio (30 Apr 2024) 49.38
Short % of float (30 Apr 2024) 48.63%
Short % of shares outstanding (30 Apr 2024) 47.36%
Shares short (prior month 28 Mar 2024) 49.41M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -46.46%
Operating margin (ttm)-70.46%

Management effectiveness

Return on assets (ttm)-8.70%
Return on equity (ttm)-11.33%

Income statement

Revenue (ttm)295.39M
Revenue per share (ttm)2.10
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -207.2M
Net income avi to common (ttm)-137.24M
Diluted EPS (ttm)-0.92
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)936.87M
Total cash per share (mrq)6.57
Total debt (mrq)50.55M
Total debt/equity (mrq)3.47%
Current ratio (mrq)11.79
Book value per share (mrq)10.21

Cash flow statement

Operating cash flow (ttm)-412.81M
Levered free cash flow (ttm)-343.06M